---
title: "Direct-to-participant double-blind trial for Long COVID: design and early operational insights"
id: "medrxiv-17-insights-from-a-double-blind-randomized-direct-to-participant-intervention"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-insights-from-a-double-blind-randomized-direct-to-participant-intervention"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1?rss=1"
published_at: "2026-08-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Direct-to-participant double-blind trial for Long COVID: design and early operational insights
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-insights-from-a-double-blind-randomized-direct-to-participant-intervention
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1?rss=1)
- **Published At:** 2026-08-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors report design and early operational outcomes from a double-blind, placebo-controlled, phase 2 trial of **tirzepatide** for fatigue in people with **Long COVID**, conducted using a fully remote, direct-to-participant (siteless) infrastructure. - The trial operates under an **FDA Investigational New Drug (IND)** authorization and received ethical approval from the Scripps Institutional Review Board. - Remote trial components included electronic consent, document-based identity and diagnosis verification, cold-chain delivery of an injectable study drug from a central pharmacy, shared decision-making for dose titration, at-home capillary blood collection in a biospecimen subcohort, weekly contacts through a study application, wrist-worn wearable monitoring, and clinical support. - Enrollment was rapid: 1,058 participants enrolled in 73 days, at least double the accrual rate reported for other Long COVID trials to date. - Baseline measures indicate a severely affected cohort: mean Fatigue Severity Scale 59.3 (SD 4.9); mean daily step count 3,611 (SD 2,706) versus a general population reference mean of 7,731; EQ-5D-5L mean 0.6 (SD 0.2); FUNCAP27 mean 4.0 (SD 1.0). - The siteless processes functioned as designed and enabled recruitment of participants who are often excluded by site-based trials, including more severely affected individuals. - The authors highlight the potential for decentralized infrastructure to scale repurposing trials of drugs with existing safety profiles, but note that modernization of drug distribution and regulatory pathways is needed to fully realize the model’s potential. - Data are part of an ongoing, blinded trial and will be shared upon publication of trial results. Competing interests for some authors and funders are declared in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=rM0RHoBCWukGHQFtBUyaKBySV5ZYjzH1RxoMVyW858c-1787501364.6796522-1.2.1.1-KfASsljr8yVOyh70yRg_7U6wKtXs2V_UoJxCxoveNJAjSq1CmfX1V_JaQGUFMXze) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID [ View ORCID Profile](http://orcid.org/0000-0002-4902-3540)Julia Moore Vogel, Janna Ter Meer, Romina Foster-Bonds, Mario Patrice Duff, Andrea Goosen, Anastasia Kurakova, Ethan Dinh-Luong, Lena Miyasaki, Sarah Topol, Cynde Sturm, Chris Nowak, Ashley Tate, John Redd, Colin Shepard, Vik Kheterpal, Steven R Steinhubl, Eric J Topol doi: https://doi.org/10.64898/2026.08.19.26360832 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Julia Moore Vogel 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julia%2BMoore%2BVogel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vogel%20JM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulia%2BMoore%2BVogel%2B) * [ORCID record for Julia Moore Vogel](http://orcid.org/0000-0002-4902-3540 "Open in new tab") * For correspondence: jmoorevogel@gmail.com Janna Ter Meer 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Janna%2BTer%2BMeer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ter%20Meer%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJanna%2BTer%2BMeer%2B) Romina Foster-Bonds 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Romina%2BFoster-Bonds%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Foster-Bonds%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARomina%2BFoster-Bonds%2B) Mario Patrice Duff 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mario%2BPatrice%2BDuff%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Duff%20MP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMario%2BPatrice%2BDuff%2B) Andrea Goosen 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrea%2BGoosen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Goosen%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrea%2BGoosen%2B) Anastasia Kurakova 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anastasia%2BKurakova%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kurakova%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnastasia%2BKurakova%2B) Ethan Dinh-Luong 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ethan%2BDinh-Luong%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dinh-Luong%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEthan%2BDinh-Luong%2B) Lena Miyasaki 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lena%2BMiyasaki%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Miyasaki%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALena%2BMiyasaki%2B) Sarah Topol 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2BTopol%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Topol%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2BTopol%2B) Cynde Sturm 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Cynde%2BSturm%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sturm%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACynde%2BSturm%2B) Chris Nowak 2 CareEvolution; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chris%2BNowak%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nowak%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChris%2BNowak%2B) Ashley Tate 2 CareEvolution; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ashley%2BTate%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tate%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAshley%2BTate%2B) John Redd 3 Schmidt Initiative for Long COVID; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=John%2BRedd%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Redd%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohn%2BRedd%2B) Colin Shepard 3 Schmidt Initiative for Long COVID; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Colin%2BShepard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shepard%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AColin%2BShepard%2B) Vik Kheterpal 2 CareEvolution; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vik%2BKheterpal%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kheterpal%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVik%2BKheterpal%2B) Steven R Steinhubl 4 Purdue University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Steven%2BR%2BSteinhubl%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Steinhubl%20SR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASteven%2BR%2BSteinhubl%2B) Eric J Topol 1 Scripps Research; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Eric%2BJ%2BTopol%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Topol%20EJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEric%2BJ%2BTopol%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1283944/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1283944/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1283944/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1283944/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1283944/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background. Long COVID affects an estimated 400 million people worldwide, and is associated with low quality of life. Nearly all completed Long COVID clinical trials reported no benefit, and most required participants to travel to study sites. This requirement systematically excludes severely affected patients. Because there are numerous candidate therapeutics with established safety profiles and regulatory approvals for other indications, scaled, efficient evaluation of therapeutics is needed. Methods. We designed and are conducting a double-blind, placebo-controlled, phase two trial of tirzepatide for Long COVID fatigue, using an entirely remote infrastructure. Design elements included electronic consent, identity and diagnosis verification through document upload, cold-chain delivery of an injectable study drug through a central pharmacy, shared decision-making for dose titration, repeated at-home capillary blood collection in a biospecimen subcohort, weekly participant touch points through study application, wrist-worn wearable monitoring, and clinical support. The trial is operating under FDA Investigational New Drug authorization. Results. This trial enrolled 1,058 participants in 73 days, at least double the rate of any other Long COVID trial. Mean baseline metrics include mean Fatigue Severity Scale of 59.3 (standard deviation [SD] 4.9), daily step count of 3,611 (SD 2,706, general population reference mean 7,731), EQ-5D-5L of 0.6 (SD 0.2), and FUNCAP27 4.0 (SD 1.0), which was a more severely affected population than other clinical trials that collected comparable data. Study processes are working as designed. Participants use existing advocacy and support channels to gather and communicate. Conclusions. A direct-to-participant, siteless infrastructure can support a double-blind placebo-controlled trial of an injectable drug at scale, accelerate accrual, and reach severely affected participants who are routinely excluded by site-based designs. Modernizing drug distribution and regulatory pathways is needed to realize the full potential of decentralized infrastructure for drug repurposing clinical trials. ### Competing Interest Statement CN, AT, and VK are employees of CareEvolution. VK is also a CareEvolution shareholder. ### Clinical Trial NCT07128082 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The trial operates under FDA Investigational New Drug (IND) authorization, was reviewed and given ethical approval by the Scripps Institutional Review Board. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data are part of an ongoing, blinded clinical trial and will be made available with the publication of trial results. ## Funder Information Declared Schmidt Initiative For Long COVID National Institutes of Health, https://ror.org/01cwqze88, UM1TR004407 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.19.26359587v1 "Pragmatic vs. naive genetic instrument selection in Mendelian randomization studies: a practical guide")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.19.26359329v1 "Vision Language Models Fail to Reliably Detect Acute Myeloid Leukemia in Bone Marrow Smears") Posted August 22, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/22/2026.08.19.26360832.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.19.26360832v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/22/2026.08.19.26360832.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID Julia Moore Vogel, Janna Ter Meer, Romina Foster-Bonds, Mario Patrice Duff, Andrea Goosen, Anastasia Kurakova, Ethan Dinh-Luong, Lena Miyasaki, Sarah Topol, Cynde Sturm, Chris Nowak, Ashley Tate, John Redd, Colin Shepard, Vik Kheterpal, Steven R Steinhubl, Eric J Topol medRxiv 2026.08.19.26360832; doi: https://doi.org/10.64898/2026.08.19.26360832 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360832v1%26text%3DInsights%2520from%2520a%2520double-blind%252C%2520randomized%252C%2520direct-to-participant%2520intervention%2520trial%2520for%2520Long%2520COVID "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360832v1%26t%3DInsights%2520from%2520a%2520double-blind%252C%2520randomized%252C%2520direct-to-participant%2520intervention%2520trial%2520for%2520Long%2520COVID "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360832v1%26title%3DInsights%2520from%2520a%2520double-blind%252C%2520randomized%252C%2520direct-to-participant%2520intervention%2520trial%2520for%2520Long%2520COVID%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360832v1%26title%3DInsights%2520from%2520a%2520double-blind%252C%2520randomized%252C%2520direct-to-participant%2520intervention%2520trial%2520for%2520Long%2520COVID "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.19.26360832) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.19.26360832v1&count=horizontal&via=&text=Insights%20from%20a%20double-blind%2C%20randomized%2C%20direct-to-participant%20intervention%20trial%20for%20Long%20COVID&counturl=www.medrxiv.org/content/10.64898/2026.08.19.26360832v1 "Tweet This") ## Subject Area * [Infectious Diseases (except HIV/AIDS) ](https://www.medrxiv.org/collection/infectious_diseases) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md)
- [Tirzepatide preserves HSPC cycling and reduces inflammatory Ly6Chi CCR2+ monocytes during weight l](https://medichelpline.com/clinical-feed/biorxiv-2-tirzepatide-preserves-hematopoietic-stem-and-progenitor-cycling-while.md)
- [Reduced-intensity Post-Cyclophosphamide GVHD Prophylaxis for Umbilical Cord Blood Transplantation:](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-reduced-intensity-post-cyclophosphamide-based-graft-versus-host-disease.md)
- [How pre-vaccination immunity heterogeneity drives variability in vaccine effectiveness estimates](https://medichelpline.com/clinical-feed/medrxiv-5-heterogeneity-in-pre-vaccination-population-immunity-can-contribute-to.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.